NT-I7 (efineptakin alfa)

efineptakin alfa · Neoleukin Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NT-I7 (efineptakin alfa), covering 2026-03-09 to 2026-03-09. Get the full timeline:

Most recent: Clinical Trial Update: A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia [Phase 1, Phase 2]

See pricing